Aura Biosciences, Inc. (AURA) vs Starling Oncology, Inc. (STLN)
A side-by-side comparison of Aura Biosciences, Inc. and Starling Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AURA
Aura Biosciences, Inc.
$6.17HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
STLN
Starling Oncology, Inc.
$6.58HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AURA vs STLN
growth of $100 · dividends reinvested · last 1yAURA -12.3% (-12.3%/yr)STLN +8.6% (+8.6%/yr)STLN compounded faster over this window
AURA STLN
AURA vs STLN: by the numbers
- •STLN is the larger company ($658M vs $638M market cap).
- •Both run net losses; AURA's is the smaller (0.00% vs -6.18% net margin).
Metrics side by side
Valuation
| Metric | AURA | STLN |
|---|---|---|
| P/S ratio | N/A | 1.12 |
| P/B ratio | 2.02 | N/A |
Profitability
| Metric | AURA | STLN |
|---|---|---|
| Gross margin | 0.00% | 15.69% |
| Operating margin | 0.00% | -4.44% |
| Net margin | 0.00% | -6.18% |
| ROE | -41.56% | N/A |
| ROIC | -42.02% | -31.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.